Engineered Phages and Engineered and Recombinant Endolysins Against Carbapenem‐Resistant Gram‐Negative Bacteria: A Focused Review on Novel Antibacterial Strategies

Antibiotic resistance has escalated globally, affecting not only commonly used antibiotics but also last‐resort agents such as carbapenems and colistin. The rise of antibiotic‐resistant bacteria has prompted microbiologists to devise new strategies, with bacteriophages emerging as one of the most promising options. Nevertheless, certain mechanisms have been identified in bacteria that confer resistance to phages. While phage resistance is currently less widespread than antibiotic resistance, challenges such as biofilm formation, newly emerging resistance mechanisms against phages, and the natural limitations of unmodified phages have driven the advancement of engineered phages. This study aims to examine the efficacy of engineered phages and both engineered and recombinant endolysins against carbapenem‐resistant Gram‐negative bacteria (CR‐GNB). We performed a literature review through PubMed, Scopus, Web of Science, and Google Scholar, concentrating on studies that utilized these agents against carbapenem‐resistant Gram‐negative bacteria (CR‐GNB). Reviewed studies indicate potential antibacterial activity of these agents against CR‐GNB. By engineering and modifying phages, these agents exhibit improved antimicrobial efficacy, temperature stability, and membrane permeability. Furthermore, they demonstrate the ability to eliminate bacteria with multidrug‐resistant (MDR) and extensively drug‐resistant (XDR) profiles. These findings suggest the promising potential of engineered phages and endolysins for future clinical applications against CR‐GNB.